Antígenos de Neoplasias/inmunología; Vacunas contra el Cáncer/inmunología; Extractos Celulares/uso terapéutico; Células Dendríticas/inmunología; Neoplasias/inmunología; Extractos Celulares/inmunología; Humanos; Memoria Inmunológica/inmunología; Neoplasias/prevención & control; Neoplasias/terapia; Linfocitos T Citotóxicos/inmunología

AM, Cytokine-activated monocytes; Ags, Antigens; CDAMs, Cell death-associated molecules; CRT, Calreticulin; CTLs, Cytotoxic T lymphocytes; DAMPs; DAMPs, Damage-associated molecular patterns; DCs, Dendritic cells; DTH, Delayed-type IV hypersensitivity; GM-CSF, Granulocyte and macrophage colony stimulating factor; HMGB1, High-mobility group box 1 protein; HSPs, Heat shock proteins; ICD, Immunogenic cell death; MAAs, Melanoma-associated antigens; MHC, Major histocompatibility complex; MM, Malignant melanoma; NKT, Natural killer T cell; PAMPs, Pathogen-associated molecular patterns; PBMCs, Peripheral blood mononuclear cells; PCCL, Prostate cancer cell lysate; PD1, Programmed cell death protein 1; PRRs, Pattern recognition receptors; PSA, Prostate specific antigen; RAGE, Receptor for advanced glycation endproducts; SNPs, Single nucleotide polymorphisms; TAAs, Tumor-associated antigens; TAPCells, Tumor antigen presenting cells; TCRs, T cell receptors; TLRs, Toll-like receptors; TNF, Tumor necrosis factor; TRIMEL, Allogeneic melanoma cell lysate; TRIPRO, Allogeneic prostate cell lysate; Toll-like receptors; Tregs, Regulatory T lymphocytes; cancer immunotherapy; dendritic cells; immunogenic cell death